2 results
Approved WMORecruiting
1) To identify new predictors of ST, in particular of late and very late ST, and of drug eltuing stent thrombosis. 2) To observe clinical outcomes after an episode of ST.
Approved WMORecruiting
Part A: To determine the recommended phase 2 dose and schedule of the RMC-4630 and LY3214996 combination in patients with KRASm advanced CRC, NSCLC and PDAC.Part B: To determine the safety and tolerability of RMC-4630 in combination with LY3214996…